Return to CBI Antibody Core Home Page
  Return to biothreat/emerging pathogens list
    Return to malaria parasite (malaria (P. falciparum)) ( Plasmodium falciparum ) list


malaria parasite (malaria (P. falciparum)) ( Plasmodium falciparum )
PFD1160w


Links to multiple antibodies on this page for PFD1160w:
PFD1160w-a
PFD1160w-b

Antibody Name/Abbreviation: PFD1160w-a
CBI Antibody Core Code: A1373a

"Lot" Number: 1 Position: To be posted
% Identical Homology of Target to Mouse Protein: 35% (NP_077207.2| kinesin family member 23; kinesin-like 5 (mitotic kinesin-like protein 1))
Molecular Weight of fusion protein: 25 KDa

Target sequence used to make this antibody:
IIHEHQEMEETTEEGASIIERHSRTSSQNNDAGTSDYMYR
ILSTTMEFPNEKETFGLYSPVSQTFDRALNFLRSVFISSS
SPVSQSKGQSKESQLAQIST






Antibody Name/Abbreviation: PFD1160w-b
CBI Antibody Core Code: A1373b

"Lot" Number: 1 Position: 100 (2280-2379)
% Identical Homology of Target to Mouse Protein: 36% (NP_079971.2| SMC6 protein)
Molecular Weight of fusion protein: N.A. KDa

Target sequence used to make this antibody:
NDLDNSIYTNLYDDTNKFFFFNENCEGVKSIYQEIEENVE
KRYTDDIYLLENEKHHNEFNTHMGENNYDVKEKMDDRNNK
NCYMRSYIKPRDKKKNTENK






Sequence Name: PFD1160w
Full name:
UniGene Number: N.A.
Accession Number: N.A.
Source organism: malaria parasite (malaria (P. falciparum)) ( Plasmodium falciparum )
Full length size (aa): 2380
NCBI information page:

Full length sequence:
MLFVVELDSRLEKSADKRISVERFRKIFEIYVEDKLEELKRSGSEKYDKD
CRDFNYFIDDVKDVFINNDLVKIPVKVRKSIWETHVDKNLPKLMKNTTSC
KCIRKEHNYNKEYRDMTRTLEDFCEEKTRKLEIIYQKDYDESLYVNFNEW
INKKKEDILKEYEKLSNKDKYKHLLKISETCDLNHVDKLFLNISSEDMKK
MKEDVKKQHLEVKVRPPVNEPIDDRGKEDALSRGGKSIILNKEENSPTEE
ITTEYNPVSEMGVGTTIAHSEPGPKTVNTEVRNVLRSDGKISDQGSQKSP
PKELSNKQMTPAQRKNVPHFVERRGYGNSHVRGNALKKISNGDDNYKSPS
SNYIEVDCAEDKYFLLEDGTNQSENSCKTKYNYFVSNDYDGTGSAIYSTD
QVPSREEIKSPDSLSTLDARGSTHNLNVSNEGNPLEGGEEKNNVKISEQN
GRNLESSVGTDKGSDKNEEEVAATCDPNDRNCFDGRYINVDYIRGLLKGK
RSGSDGRSNIKHIISNNFDDSNMIFPTFNFDFDILKAEEEVLPVNNSDII
YGHEEVEETTQEGASIFEKHSHTSSQQNDSSASGNKYRMLSTTMELPNQQ
EVFGLYSPVSRTLDSAMSFLRSIISLSSAPVSRSEGQSKESKRVEISTTV
QDPIGYRTSPLQMNAHSVGAGINVSSILSMLGLSSGQVRRSGGQGSETYI
VGTSQSGFHKNEVIPSIKDKSGKTQIVSNEKGGIFSKGITSMMSSLPVAL
VTFVFLFMFLVFNKMNPFGTTIVQGKKKKKVKQKLGERKKPKRRSAKRRR
GVDVNMEEEINKIIYTNEFNNYEDKIYEDVKYIKEQENEMYLRDGIEELH
MDEPSGDVYFDDQDDYIFLDEQKEDVCLDEAKNDILSKESFDDVLIKVVD
REINREINGKINGEINREINGEINGEMNREINREINGEINGKINREINRE
INGEIPLKKEKWMWKTILEIEMKVVEKCKKEEWEESKGDFLEICLDEFIK
KENEYNKIHNKVIIEKSVLENQNMLWNKWIERHRYMLEKWKKEEWFYNLK
NEWINEIENYEKKESDIEIILPSEKKTRNISLEKQKIIWRRWVARYVQHI
DDDIIEEWFKKMMAEYEKEEYYLNKNRYKIINHIRNRNDKHDENVQCDDE
ESLVSSSICFDVEEKKKKNLLTKIWFQIHMMILEEYKKDECIHIKNLLLD
NYIDNLKKKNELDAKKKLQKLDILNEMKKENNIIDINERNKWEGEKWFED
LNNEWNDYERTYIKNNFVIKKENDMNIKYEYIIIDEPLMKVKKDIPQMHW
KNIYEKWLHDEYKYVYRCEDINKSVDEKRDNNIDIGESINVKNNEVMKEK
KVKWKTIIEIYMEVMNEYKKDEWEEHRGDFLQICLEEFIKKDNDEMRNIN
DELYIEQSDHMEDMLMLERQKIRWLQWINRNKYMLEKWNKEEWFCKLKKD
WEDEKNRYDEKLFLWKNTENDKYINPMLERQKYIWRKWIAKHLYHIDEWE
NEEWFKLLMSTYEKDRDDLKRDHPINKMDDMEKKKLITKLFIEIHMMVIE
DFKKEECYRNKQTFVDTYINEMKKEEPCEKNREMLNILNNIKKDIKLGYE
NTKMNEWKEEKWFDKLKKEWKEGECKNFVDIEKENFDKTQVNVINNYMLE
IQRSLLKKYWQDVEISWIDDDNQTDWLKIAIHMDDYDNKNKVYNRRHDYM
RNKNLHVKKKKNIINEDHLSEDNKYLHENNHSYIKRIIEIYMERVNKIQK
KEWEENKRDFLKIALAEYIKMQFDKQKNLCIEEMVIKNKNINDDNNGYLE
PAFLWNQWVERKRYIMEKWKYEKWFEELKIEWVKEQGIYIKEEEINTFMK
DEKKENNKIIHNDKIIHNDKIIHNDKIIHNNKIINNNNDILIESEKIVWR
RWLKKQEQNIQIYKNKKWFKDIIVEFEKDEEDDMIMYSNVNDISKVNNKE
VDVNNRDNLIMKIWICICMMILEECKKDEGRYNKEIFLNSFIKEIKKEKD
EKIKMNMLDMILQMKEKYISKNEKDFYIYDWKKEKWFEDLKNDCKNNKNE
YIYMLQNDLCKRYWKDLDKMWLENEDKIKRNMLTNIYEEYNNMDDLSKKE
YIHKNINIINENMKCNSEVEKTHGEHTVEGIKNYYLEKQKEIWRQWIEKN
VKHINQSTKEQEQILVDTENNKIVNSSDCKKNENKNEPYYMKKKNLKTVF
LAEIHMETMDRCKGLNYKGEDKIETDENIKELKIEEGENSKTNYIHKTIL
PKDECKKSKLSLNEENKMCKHKNMKENKINDLDNSIYTNLYDDTNKFFFF
NENCEGVKSIYQEIEENVEKRYTDDIYLLENEKHHNEFNTHMGENNYDVK
EKMDDRNNKNCYMRSYIKPRDKKKNTENKT





Questions? Click here for answers.


© Monday, February 16, 2009 by the CBI Antibody Core and the Center for Biomedical Inventions, University of Texas Southwestern Medical School.